Hector Cajigas

Dr. Hector Cajigas

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2024 in Chest
Verified
Journal Article
Open access
AYAthiththan Yogeswaran
Athiththan Yogeswaran
HGHenning Gall
Henning Gall
MFMeike Fünderich
Meike Fünderich
MWMartin R. Wilkins
Martin R. Wilkins
LHLuke Howard
Luke Howard
AVAndreea Varga
Andreea Varga
Pulmonary hypertension (PH) is a heterogeneous disease with a poor prognosis. Accurate risk stratification is essential for guiding treatment decisions in pulmonary arterial hypertension (PAH). Although various risk models have been developed for PAH, their comparative prognostic potential requires further exploration. Additionally, the applicability of risk scores in PH groups beyond group 1 remains to be investigated. Are risk scores originally developed for PAH predictive in PH groups 1 through 4? We conducted a comprehensive analysis of outcomes among patients with incident PH enrolled in the multicenter worldwide Pulmonary Vascular Research Institute GoDeep meta-registry. Analyses were performed across PH groups 1 through 4 and further subgroups to evaluate the predictive value of PAH risk scores, including the Registry to Evaluate Early and Long-Term PAH Disease Mangement (REVEAL) Lite 2, REVEAL 2.0, European Society of Cardiology/European Respiratory Society 2022, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) 3-strata, and COMPERA 4-strata. Eight thousand five hundred sixty-five patients were included in the study, of whom 3,537 patients were assigned to group 1 PH, whereas 1,807 patients, 1,635 patients, and 1,586 patients were assigned to group 2 PH, group 3 PH, and group 4 PH, respectively. Pulmonary hemodynamics were impaired with median mean pulmonary arterial pressure of 42 mm Hg (interquartile range, 33-52 mm Hg) and pulmonary vascular resistance of 7 Wood units (WU) (interquartile range, 4-11 WU). All risk scores were prognostic in the entire PH population and in each of the PH groups 1 through 4. The REVEAL scores, when used as continuous prediction models, demonstrated the highest statistical prognostic power and granularity; the COMPERA 4-strata risk score provided subdifferentiation of the intermediate-risk group. Similar results were obtained when separately analyzing various subgroups (PH subgroups 1.1, 1.4.1, and 1.4.4; PH subgroups 3.1 and 3.2; group 2 with isolated postcapillary PH vs combined precapillary and postcapillary PH; patients of all groups with concomitant cardiac comorbidities; and severe [> 5 WU] vs nonsevere PH). This comprehensive study with real-world data from 15 PH centers showed that PAH-designed risk scores possess predictive power in a large PH cohort, whether considered as common to the group or calculated separately for each PH group (1-4) and various subgroups. ClinicalTrials.gov; No.: NCT05329714; URL: www. gov.


3 November 2022 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
HCHector Cajigas
Hector Cajigas
CBCharles D. Burger
Charles D. Burger
RCRodrigo Cartin-Ceba
Rodrigo Cartin-Ceba
HDHilary DuBrock
Hilary DuBrock
KSKaren Swanson
Karen Swanson
MKMichael Krowka
Michael Krowka

1 January 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
JAJason H. Anderson
Jason H. Anderson
ACAllison K. Cabalka
Allison K. Cabalka
RFRobert P. Frantz
Robert P. Frantz
HCHector Cajigas
Hector Cajigas
NTNathaniel W. Taggart
Nathaniel W. Taggart

1 October 2023 in Pulmonary Circulation
Verified
Journal Article
Open access
HCHector Cajigas
Hector Cajigas
BLBen Lavon
Ben Lavon
WHWilliam Harmsen
William Harmsen
PMPatrick Muchmore
Patrick Muchmore
JCJoana Costa
Joana Costa
JBJan De Backer
Jan De Backer
To determine whether quantitative computed tomography (qCT)‐derived metrics of pulmonary vascular volume distribution could distinguish chronic obstructive pulmonary disease (COPD) subjects with associated pulmonary hypertension (PH) from those without and to characterize associations of these measurements with clinical and physiological characteristics and outcomes. We collected retrospective CT, pulmonary hemodynamic, clinical, and outcomes data from subjects with COPD and right‐heart catheterization‐confirmed PH (PH‐COPD) and control subjects with COPD but without PH. We measured the volumes of pulmonary vessels < 5 and >10 mm2 in cross‐sectional area as a percentage of total pulmonary vascular volume (qCT‐derived volume of pulmonary vessels < 5 mm2 in cross‐sectional area as a volume fraction of total pulmonary blood volume [BV5%] and qCT‐derived volume of pulmonary vessels > 10 mm2 in cross‐sectional area [BV10] as a volume fraction of total pulmonary blood volume [BV10%], respectively) using Functional Respiratory Imaging (FRI), an automated qCT platform, and compared them between PH and control arms and between subjects with mild‐moderate PH and those with severe disease. Correlations of hemodynamics with pulmonary function and associations with survival were tested. Forty‐five PH‐COPD and 42 control subjects were studied. BV5% was lower in PH subjects (32.2% vs. 37.7%, p = 0.003), and BV10% was higher (50.2% vs. 43.5, p = 0.001). Subjects with severe PH did not differ from those with mild‐moderate PH in qCT. Pulmonary vascular volumes were not associated with pulmonary function. BV10 was associated with mean pulmonary artery pressure (r = 0.3, p = 0.05). Associations with survival were observed for BV5% (hazard ratio 0.63, p = 0.02) and BV10% (hazard ratio 1.43, p = 0.03) in the PH‐COPD arm, but not for controls. qCT‐derived measures of pulmonary vascular volume may have diagnostic and prognostic significance in PH‐COPD and should be investigated further as screening and risk stratification tools

8 November 2024 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
CBCharles Burger
Charles Burger
HSHollie Saunders
Hollie Saunders
DHDavid O. Hodge
David O. Hodge
RSRobert E. Safford
Robert E. Safford
SHScott Helgeson
Scott Helgeson
MKMichael J. Krowka
Michael J. Krowka